1932

Abstract

Despite rapid advances in the field of HIV prevention and treatment, unacceptably high global HIV incidence rates highlight the ongoing need for effective HIV prevention interventions for populations at risk for HIV acquisition. This article provides an updated review of the current data surrounding HIV prevention strategies, including treatment as prevention (TasP), preexposure prophylaxis (PrEP), and postexposure prophylaxis (PEP), as well as advances in sexually transmitted infection biomedical prevention. This review provides an overview of the multiple PrEP modalities that are available globally, such as oral PrEP, injectable cabotegravir, and the dapivirine vaginal ring, and describes their respective clinical trials, efficacies, and regulatory approvals. We also discuss ongoing research into novel PrEP agents, such as broadly neutralizing antibodies, and efforts toward HIV vaccine development.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-042823-013707
2025-01-27
2025-02-07
Loading full text...

Full text loading...

/deliver/fulltext/med/76/1/annurev-med-042823-013707.html?itemId=/content/journals/10.1146/annurev-med-042823-013707&mimeType=html&fmt=ahah

Literature Cited

  1. 1.
    Trickey A, Sabin CA, Burkholder G, et al. 2023.. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. . Lancet HIV 10:(5):e295307
    [Google Scholar]
  2. 2.
    UNAIDS (Jt. U. N. Programme HIV/AIDS). 2024.. Fact Sheet 2024. Geneva:: UNAIDS. https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf
    [Google Scholar]
  3. 3.
    Cohen M, Chen Y, McCauley M, et al. 2011.. Prevention of HIV-1 infection with early antiretroviral therapy. . N. Engl. J. Med. 365:(6):493505
    [Google Scholar]
  4. 4.
    Mayer K, Beyrer C. 2013.. WHO's new HIV guidelines: opportunities and challenges. . Lancet 382:(9889):28788
    [Google Scholar]
  5. 5.
    Rodger A, Cambiano V, Bruun T, et al. 2019.. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. . Lancet 393:(10189):242838
    [Google Scholar]
  6. 6.
    Rodger A, Cambiano V, Bruun T, et al. 2016.. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. . JAMA 316:(2):17181
    [Google Scholar]
  7. 7.
    Bavinton B, Pinto A, Phanuphak N, et al. 2018.. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. . Lancet HIV 5:(8):e43847. Correction. 2018. Lancet HIV 5:(10):e545
    [Google Scholar]
  8. 8.
    Hayes R, Donnell D, Floyd S, et al. 2019.. Effect of universal testing and treatment on HIV incidence—HPTN 071 (PopART). . N. Engl. J. Med. 381:(3):20718
    [Google Scholar]
  9. 9.
    Havlir D, Balzer L, Charlebois E, et al. 2019.. HIV testing and treatment with the use of a community health approach in rural Africa. . N. Engl. J. Med. 381:(3):21929
    [Google Scholar]
  10. 10.
    Dominguez KL, Smith DK, Thomas V, et al. 2016.. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016. Rep. , Cent. Dis. Control Prev., Atlanta:. https://stacks.cdc.gov/view/cdc/38856
    [Google Scholar]
  11. 11.
    Grant R, Lama J, Anderson P, et al. 2010.. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. . N. Engl. J. Med. 363:(27):258799
    [Google Scholar]
  12. 12.
    Van Damme L, Corneli A, Ahmed K, et al. 2012.. Preexposure prophylaxis for HIV infection among African women. . N. Engl. J. Med. 367:(5):41122
    [Google Scholar]
  13. 13.
    Thigpen M, Kebaabetswe P, Paxton L, et al. 2012.. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. . N. Engl. J. Med. 367:(5):42334
    [Google Scholar]
  14. 14.
    Baeten J, Donnell D, Ndase P, et al. 2012.. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. . N. Engl. J. Med. 367:(5):399410
    [Google Scholar]
  15. 15.
    Marrazzo J, Ramjee G, Richardson B, et al. 2015.. Tenofovir-based preexposure prophylaxis for HIV infection among African women. . N. Engl. J. Med. 372:(6):50918
    [Google Scholar]
  16. 16.
    Molina J, Capitant C, Spire B, et al. 2015.. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. . N. Engl. J. Med. 373:(23):223746
    [Google Scholar]
  17. 17.
    Antoni G, Tremblay C, Delaugerre C, et al. 2020.. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial. . Lancet HIV 7:(2):e11320
    [Google Scholar]
  18. 18.
    Molina J, Ghosn J, Assoumou L, et al. 2022.. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study. . Lancet HIV 9:(8):e55462
    [Google Scholar]
  19. 19.
    Mayer K, Molina J, Thompson M, et al. 2020.. Emtricitabine and tenofovir alafenamide versus emtri-citabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. . Lancet 396:(10246):23954
    [Google Scholar]
  20. 20.
    Yager J, Brooks K, Castillo-Mancilla J, et al. 2021.. Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/tenofovir alafenamide versus emtricitabine/tenofovir disoproxil fumarate. . AIDS 35:(15):248187
    [Google Scholar]
  21. 21.
    Bekker LG, Das M, Abdool Karim Q, et al. 2024.. Twice-yearly lenacapavir or daily f/taf for HIV prevention in cisgender women. . N. Engl. J. Med. 391::117992
    [Google Scholar]
  22. 22.
    Landovitz R, Donnell D, Clement M, et al. 2021.. Cabotegravir for HIV prevention in cisgender men and transgender women. . N. Engl. J. Med. 385:(7):595608
    [Google Scholar]
  23. 23.
    Eshleman SH. 2023.. The LEVI syndrome: characteristics of early HIV infection with cabotegravir for PrEP. Paper presented at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA:, Feb. 21
    [Google Scholar]
  24. 24.
    Landovitz R, Delany-Moretlwe S, Fogel JM, et al. 2024.. Features of HIV infection in the context of long-acting cabotegravir preexposure prophylaxis. . N. Engl. J. Med. 391::125356
    [Google Scholar]
  25. 25.
    Delany-Moretlwe S, Hughes J, Bock P, et al. 2022.. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. . Lancet 399:(10337):177989
    [Google Scholar]
  26. 26.
    Marzinke M. 2023.. Cabotegravir pharmacology in the background of delayed injections in HPTN 084. Paper presented at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA:, Feb. 21
    [Google Scholar]
  27. 27.
    Harris M. 2023.. Lenacapavir: an attractive option, but proceed with caution. . Lancet HIV 10:(8):e48687
    [Google Scholar]
  28. 28.
    Gilead. 2024.. Gilead presents additional efficacy, safety, and demographic data from PURPOSE 2 trial at 5th HIV Research for Prevention Conference. News Release, Oct. 7. https://www.gilead.com/news/news-details/2024/gilead-presents-additional-efficacy-safety-and-demographic-data-from-purpose-2-trial-at-5th-hiv-research-for-prevention-conference
    [Google Scholar]
  29. 29.
    Kelley C. 2024.. Twice-yearly lenacapavir for HIV prevention in cisgender gay men, transgender, and gender-diverse people: interim analysis result from the PURPOSE 2 study. Oral abstract presented at the 2024 International AIDS Society HIV Research for Prevention (IAS HIVR4P) Conference, Lima, Peru:, Oct. 8
    [Google Scholar]
  30. 30.
    Nel A, van Niekerk N, Kapiga S, et al. 2016.. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. . N. Engl. J. Med. 375:(22):213343
    [Google Scholar]
  31. 31.
    Baeten JM, Palanee-Phillips T, Brown ER, et al. 2016.. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. . N. Engl. J. Med. 375:(22):212132
    [Google Scholar]
  32. 32.
    Baeten JM, Palanee-Phillips T, Mgodi NM, et al. 2021.. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. . Lancet HIV 8:(2):e8795
    [Google Scholar]
  33. 33.
    Nel A, van Niekerk N, Van Baelen B, et al. 2021.. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study. . Lancet HIV 8:(2):e7786
    [Google Scholar]
  34. 34.
    Nair G, Celum C, Szydlo D, et al. 2023.. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial. . Lancet HIV 10:(12):e77989
    [Google Scholar]
  35. 35.
    Spencer D, Shapiro M, Haigwood N, Hessell A. 2021.. Advancing HIV broadly neutralizing antibodies: from discovery to the clinic. . Front. Public Health 9::690017
    [Google Scholar]
  36. 36.
    Corey L, Gilbert P, Juraska M, et al. 2021.. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. . N. Engl. J. Med. 384:(11):100314
    [Google Scholar]
  37. 37.
    Merck. 2021.. Merck announces clinical holds on studies evaluating islatravir for the treatment and prevention of HIV-1 infection. News Release, Dec. 13
    [Google Scholar]
  38. 38.
    Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. 2009.. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. . N. Engl. J. Med. 361:(23):220920
    [Google Scholar]
  39. 39.
    Gray G, Bekker L, Laher F, et al. 2021.. Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults. . N. Engl. J. Med. 384:(12):1089100
    [Google Scholar]
  40. 40.
    NIH (Natl. Inst. Health). 2021.. HIV vaccine candidate does not sufficiently protect women against HIV infection. News Release, Aug. 31
    [Google Scholar]
  41. 41.
    NIH (Natl. Inst. Health). 2023.. Experimental HIV vaccine regimen safe but ineffective, study finds. News Release, Jan. 18
    [Google Scholar]
  42. 42.
    Kuhar DT, Henderson DK, Struble KA, et al. 2013.. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. . Infect. Control Hosp. Epidemiol. 34:(9):87592
    [Google Scholar]
  43. 43.
    CDC (Cent. Dis. Control Prev.). 2024.. Clinical guidance for PEP. . CDC. https://www.cdc.gov/hivnexus/hcp/pep/index.html
    [Google Scholar]
  44. 44.
    Mayer KH, Gelman H, Holmes J, et al. 2022.. Safety and tolerability of once daily coformulated bictegravir, emtricitabine, and tenofovir alafenamide for postexposure prophylaxis after sexual exposure. . J. Acquir. Immune Defic. Syndr. 90:(1):2732
    [Google Scholar]
  45. 45.
    Tan DH, Persaud R, Qamar A, et al. 2024.. BIC/FTC/TAF as HIV PEP was well-tolerated with high adherence and no seroconversions. Poster presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI), Denver, CO:, March 3
    [Google Scholar]
  46. 46.
    Molina J, Charreau I, Chidiac C, et al. 2018.. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. . Lancet Infect. Dis. 18:(3):30817
    [Google Scholar]
  47. 47.
    Luetkemeyer A, Donnell D, Dombrowski J, et al. 2023.. Postexposure doxycycline to prevent bacterial sexually transmitted infections. . N. Engl. J. Med. 388:(14):1296306
    [Google Scholar]
  48. 48.
    Molina J-M. 2023.. ANRS 174 DOXYVAC: an open-label randomized trial to prevent STIs in MSM on PrEP. Paper presented at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA:, Feb. 20
    [Google Scholar]
  49. 49.
    Stewart J, Oware K, Donnell D, et al. 2023.. Doxycycline prophylaxis to prevent sexually transmitted infections in women. . N. Engl. J. Med. 389:(25):233140
    [Google Scholar]
  50. 50.
    Sok D, Burton DR. 2018.. Recent progress in broadly neutralizing antibodies to HIV. . Nat. Immunol. 19:(11):117988
    [Google Scholar]
  51. 51.
    Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. 2010.. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. . Science 329:(5996):116874
    [Google Scholar]
  52. 52.
    Delany-Moretlwe S, Lombard C, Baron D, et al. 2018.. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. . Lancet Infect. Dis. 18:(11):124150
    [Google Scholar]
  53. 53.
    McCormack S, Dunn DT, Desai M, et al. 2016.. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. . Lancet 387:(10013):5360
    [Google Scholar]
/content/journals/10.1146/annurev-med-042823-013707
Loading
/content/journals/10.1146/annurev-med-042823-013707
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error